Cervical cancer
Conditions
Interventions
Group A:Dexmedetomidine 1 ug/kg will be intranasally administered
Group B:Dexmedetomidine 0.5 ug/kg combined with s-ketamine 0.5 mg/kg will be intranasally administered
Sponsors
Third People's Hospital of Chengdu Affiliated to Southwest Jiaotong University
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Cervical cancer was diagnosed by histopathology; 2. Meeting the guidelines for brachytherapy of cervical cancer: positive incisal margin, maximum diameter of tumor greater than 4 cm, positive pelvic lymph nodes or paracardiac invasion, vascular tumor embolus, cervical invasion depth of 1/3 to 1/2 or more, as long as meeting one of them, postoperative radiotherapy is required; Cervical cancer subjects with FIGO stage IB3-IVA with difficulty or inoperable surgery were treated with radical radiotherapy; 3. Aged >18 years and <= 65 years old, female; 4. ASA Grade I-III; 5. BMI 18-30kg/m^2; 6. Subjects voluntarily participate in this experiment and sign the consent form.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to the drugs used in this study; 2. Acute heart failure, unstable angina pectoris, myocardial infarction within 6 months before chemotherapy, resting electrocardiogram heart rate <=50 beats/min, third-degree atrioventricular block and other severe arrhythmias, and severe heart valve disease; 3. Patients with severe respiratory diseases, liver and kidney insufficiency; 4. Known rhinitis or abnormal nasal anatomy; 5. Patients judged to have difficulty in airway management; 6. Patients who used sedative and analgesic drugs other than study drugs before surgery; 7. Patients with recent craniocerebral injury, cerebral infarction, cerebral hemorrhage and central nervous system diseases; 8. Mental diseases (schizophrenia, mania, insanity, etc.) and a history of long-term use of psychotropic drugs, unable to communicate; 9. Incomplete data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Modified Observer's Assessment of Alert;Visual analogue scale pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| The onset time of sedation;X-ray fluoroscopy time;Installation time of radiation device; | — |
Countries
China
Contacts
Public ContactChi Xiaowei
Third People's Hospital of Chengdu Affiliated to Southwest Jiaotong University
Outcome results
None listed